Junshi Forms $16 Million mRNA JV with Hangzhou's Immorna
publication date: Jul 20, 2021
Shanghai Junshi Bio formed a mRNA Joint Venture with Hangzhou's Immorna to develop new drugs for cancer, plus infectious and rare diseases. Initially, the JV will have a value of $16 million with Junshi contributing half of that in cash and Immora adding in its mRNA IP for the other half. Junshi, a company best known for developing the first domestically developed PD-1 drug approved in China, said it would invest up to $123 million in the JV. Immorna focuses on process development and optimization of mRNA and delivery vehicles along with R&D of novel nucleic acid drugs. More details....
Stock Symbols: (HK: 1877; SHA: 688180)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.